Comparing the current results to its competitors, Cytokinetics Incorporated reported Revenue decrease in the 2 quarter 2026 year on year by -57.13 %, despite the revenue increase by the most of its competitors of 8.61 %, recorded in the same quarter.
Cytokinetics Incorporated's Comment on Competition and Industry Peers
MYQORZO operates in the cardiac myosin inhibitor market, focusing on obstructive hypertrophic cardiomyopathy (oHCM). Its primary competitor is Camzyos® (mavacamten), marketed by Bristol Myers Squibb. First-line standard treatments also include generic beta blockers and calcium channel blockers. Other companies conducting clinical trials for potential competing drugs include Edgewise Therapeutics, Lexicon, Tenaya, and Braveheart Bio (Hengrui). The MYQORZO label and Risk Evaluation and Mitigation Strategy (REMS) differ from those of Camzyos®, which received FDA approval in 2022 with a comprehensive and mandatory REMS. The market features various companies and institutions with potentially greater resources and capabilities that may offer competitive advantages.
September 18, 2025
This article examines the recent securities class action lawsuit filed against Cytokinetics, Incorporated (NASDAQ: CYTK), alongside a substantial increase in revenue reported for the second quarter of 2025. While the company demonstrated notable financial growth compared to its industry peers, it simultaneously faces significant legal scrutiny and shrinking market share. This analysis focuses on the implications of these developments for Cytokinetics and the broader pharmaceutical landscape.Cytokinetics, Incorporated, a biopharmaceutical company focused on developing treatments that affect muscle function and performance, recently found itself embroiled in a class action lawsuit. Gainey McKenna and Egleston ...
January 21, 2025
Exploring Cytokinetics Groundbreaking Efforts in Heart Failure Therapy Cytokinetics, Incorporated, a biotechnology company focused on developing innovative treatments for cardiac and neuromuscular diseases, has made significant strides in the clinical landscape, particularly regarding heart failure with preserved ejection fraction (HFpEF). With the initiation of the AMBER-HFpEF trial, the company aims to explore the therapeutic potential of CK-586 in a patient population that has been historically challenging to treat. AMBER-HFpEF: A New Hope for HFpEF PatientsOn January 21, 2025, Cytokinetics announced the commencement of AMBER-HFpEF, a Phase 2 clinical trial investigating CK-586, a cardiac myosin inhibito...
June 4, 2024
Cytokinetics Grants Inducement Options and Units to CFO Sung H. LeeSOUTH SAN FRANCISCO, Calif., June 04, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) has recently announced the granting of stock options, restricted stock units (RSUs), and performance stock units (PSUs) to Sung H. Lee, the company s newly appointed Executive Vice President and Chief Financial Officer. The grant of these equity awards serves as a material inducement to attract Mr. Lee to the company, whose employment began on May 8, 2024.Under the agreement, Mr. Lee will be eligible to purchase an aggregate of 53,417 shares of common stock through stock options. In addition to the stock options, 34,684 RSUs will be granted to Mr. Lee, whic...
May 13, 2024
Cytokinetics, a leading biopharmaceutical company, recently presented the primary results of the SEQUOIA-HCM clinical trial at the European Society of Cardiology Heart Failure 2024 Congress. The results, which were also published in the New England Journal of Medicine, highlighted significant improvements in the primary efficacy endpoint as well as all secondary endpoints. This groundbreaking research offers hope for patients with obstructive hypertrophic cardiomyopathy (HCM) and reinforces Cytokinetics commitment to developing innovative treatments for cardiac conditions.Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy:Cytokinetics had previously announced three late-break...
April 10, 2024
Cytokinetics, a pre-eminent bio-pharmaceutical enterprise focusing on muscle biology and related diseases, has recently announced three late-breaking clinical trial presentations that shed light on the outcomes of the SEQUOIA-HCM study at the European Society of Cardiology (ESC) Heart Failure Congress 2024. These revelations follow their primary results release, showcasing encouraging topline results in patients with Obstructive Hypertrophic Cardiomyopathy (OHC).The study s crux is Cytokinetics avant-garde drug, CK-274, which signifies a new therapeutic approach for patients with hypertrophic cardiomyopathy (HCM). HCM patients usually experience an overgrowth of heart muscles, leading to functional impairme...
April 5, 2024
:Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by abnormal thickening of the heart muscle, leading to impaired cardiac function and a range of clinical symptoms. Current treatment options for HCM focus on symptom management, and there is a critical need for novel therapies that target the underlying disease mechanism. Aficamten, a selective myosin inhibitor, has shown promise in early clinical trials for HCM. This article presents the findings from a 48-week open-label extension study, FOREST-HCM, which evaluated the long-term efficacy and safety of aficamten in HCM patients.HCM affects approximately 1 in 500 individuals worldwide, making it the most common inherited cardiovasc...
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Sources:
Cytokinetics Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cytokinetics Incorporated versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
